Roche : Invitation to Roche’s virtual event on key hematology data presented at ASH 2021
November 16, 2021 at 04:06 am
Share
Investor Update
16 November 2021
Invitation to Roche's virtual event on key hematology data presented at ASH 2021
We are pleased to invite investors and analysts to participate in our virtual event on Wednesday, 15 December, 2021, highlighting Roche data presented at the virtual American Society of Hematology (ASH) 63rd Annual Meeting, from 11-14th December.
16:00 - 17:30 CET / 15:00 - 16:30 GMT
10:00 - 11:30 am EST / 7:00 - 8:30 am PST
The webinar will start with a presentation, followed by a Q&A session (live access to the speakers).
Agenda:
Welcome
Karl Mahler, Head of Investor Relations
Hematology franchise overview
Peter Ahnesorg, Franchise Head Hematology
Review of key clinical data presented at ASH: Hemlibra, mosun, glofit, cevostamab
Charles Fuchs, Senior Vice President - Global Head Of Oncology And Hematology Product Development
Presentation of POLARIX data
Franck Morschhauser, MD, PhD, Professor of Hematology, University of Lille; President of LYSA, LYSARC
Q&A
The slides will be available for download at 15:00 CET on the day of the event. click here
Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.
Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.
A replay of the webcast will be available via ir.roche.com
*privacy notice
Best regards,
Karl Mahler
Head of Investor Relations
Loren Kalm
Head of Investor Relations, North America
Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Roche Holding AG published this content on 16 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2021 09:05:03 UTC.
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.